Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.

The Journal of clinical endocrinology and metabolism - 13 Aug 2026

Minaldi Elisa, Ramone Teresa, Ciampi Raffaele, Romei Cristina, Casalini Roberta, Gambale Carla, Prete Alessandro, Lorusso Loredana, Agate Laura, Torregrossa Liborio, Piaggi Paolo, Matrone Antonio, Elisei Rossella

Abstract excerpt

CONTEXT: The predictive role of mutational status in the response to lenvatinib in advanced radioiodine-refractory thyroid cancer (RAIR-TC) is not yet defined. OBJECTIVE: To identify a molecular signature of RAIR-TC treated with lenvatinib and its impact on clinical response to lenvatinib. DESIGN: This is a retrospective study including 49 RAIR-TC patients treated with first-line lenvatinib and followed at least...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Iodine Radioisotopes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenylurea Compounds

Share to Proto-Oncogene Proteins B-raf

Share to Quinolines

Share to Telomerase

Share to Thyroid Neoplasms

Share to Tumor Suppressor Protein p53

Source

Open in PubMed Open full text

Identifiers

PMID: 41891781
DOI: 10.1210/clinem/dgag074
PMCID: PMC13466938

Genes

TERT
TP53
BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Molecular Profile of Advanced Radioiodine-refractory Thyroid Cancer and Response to Lenvatinib Treatment.PMID 41891781Read ↗

Targeted therapy in thyroid cancer: molecular alterations and clinical management.Semantic proximity Read ↗

Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan.Semantic proximity Read ↗

Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study.Semantic proximity Read ↗

Characterization of Advanced RAS-driven Follicular-derived Thyroid Cancers and Review of Future Therapeutic Avenues.Semantic proximity Read ↗

BRAF and MEK inhibition beyond dabrafenib-trametinib in advanced thyroid cancer: a real-world case series.Semantic proximity Read ↗

TERT promoter mutations contribute to adverse clinical outcomes and poor prognosis in radioiodine refractory differentiated thyroid cancer.Semantic proximity Read ↗

TERT Promoter Mutations Contribute to Adverse Clinical Outcomes and Poor Prognosis in Radioiodine Refractory Differentiated Thyroid CancerSemantic proximity Read ↗

Update on the molecular diagnosis and targeted therapy of thyroid cancer.Semantic proximity Read ↗

Molecular predictive biomarker testing in advanced thyroid cancer - a European consensus.Semantic proximity Read ↗

Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer.Semantic proximity Read ↗

Anaplastic thyroid cancer:Improved understanding of what remains a deadly disease.Semantic proximity Read ↗

Characterizing Genetic Alterations Related to Radioiodine Avidity in Metastatic Thyroid Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.